Drug Trial Radar · NCT00801957
Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Sep 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
260
Actual
Start
Mar 2003
Primary completion
Nov 2004
Study completion Nov 2004
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Dec 4, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Seven-month study in pediatric patients (2-11 years) with moderate to severe AD who were considered to benefit from vaccination to prevent invasive disease caused by Neisseria meningitides serogroup C.
Conditions
- Atopic Dermatitis
Interventions
tacrolimus ointment 0.03%Drug
topical application
hydrocortisone acetate ointment 1%Drug
topical application
hydrocortisone butyrate ointment 0.1%Drug
topical application
MeningitecBiological
im injection
AC VAXBiological
im injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with serum bactericidal antibody titer of ≥ 8Time frame: 5 weeks
Locations
36 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Kogarah, New South Wales, Australia
Site not named
St Leonards, New South Wales, Australia
Site not named
Benowa, Queensland, Australia
Site not named
Carina Heights, Queensland, Australia
Site not named
Herston, Queensland, Australia
Site not named
North Adelaide, South Australia, Australia
Site not named
Carlton, Victoria, Australia
Site not named
Parkville, Victoria, Australia
Site not named
Fremantle, Western Australia, Australia
Site not named
Leuven, Belgium
Site not named
Bretten, Germany
Site not named
Ettenheim, Germany
Site not named
Gersfeld, Germany
Site not named
Kehl, Germany
Site not named
Tettnang, Germany
Site not named
Budapest, Hungary
Site not named
Debrecen, Hungary
Site not named
Pécs, Hungary
Site not named
Szeged, Hungary
Site not named
Kopavogur, Iceland
Site not named
Saint Julians, Malta
Site not named
Karpacz, Poland
Site not named
Krakow, Poland
Site not named
Lodz, Poland
Site not named
Lodz, Poland
Site not named
Opole, Poland
Site not named
Poznan, Poland
Site not named
Rabka-Zdrój, Poland
Site not named
Warsaw, Poland
Site not named
Warsaw, Poland
Site not named
Wroclaw, Poland
Site not named
Wroclaw, Poland
Site not named
Zabrze, Poland
Site not named
Zgierz, Poland
Site not named
Lisbon, Portugal
Site not named
Porto, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.